As CIO, Andrew will lead our new Office of Innovation, driving cutting-edge research and development while ensuring continuous advancement and integration of new technologies. He will also oversee our Quality, Regulatory, and Clinical Studies teams.     

Ali has been serving as General Counsel since mid-April 2022. She has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for over 5 years, representing the company in its acquisition of Inivata and Trapelo Health, as well as fundraising and governance activities. At NeoGenomics, she has also represented the company in various regulatory matters, including before the College of American Pathologists (CAP), the Office for Civil Rights (OCR), and the Office of Inspector General (OIG).